Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cure of hodgkin’s disease.Br Med J. 1963; 1: 1704-1707
- Definition of cure for hodgkin’s disease.Cancer Res. 1971; 31: 1828-1833
- Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials.J Clin Oncol. 2017; 35: 2900-2910
- A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.Blood Adv. 2020; 4: 5988-5999
- Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?.Blood. 2021; 138: 1901-1905
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Lancet Oncol. 2016; 17: e328-e346
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.Blood. 2011; 117: 3025-3031
- Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.J Clin Oncol. 2008; 26: 5775-5782
- Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.Haematologica. 2007; 92: 1399-1406
- Absence of contribution to a differential outcome of the stringent complete response IMWG category respect to the conventional CR in multiple myeloma. a validation analysis based on the pethema/GEM2012MENOS65 phase III clinical trial.Blood. 2018; 132: 1943
- Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure.Bone Marrow Transplant. 2002; 30: 479-484
- Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project.Blood Cancer J. 2018; 8: 1-7
- Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.Cancer. 2008; 113: 355-359
- Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis.JAMA Oncol. 2017; 3: 28
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.Blood. 2018; 132: 2456-2464
- Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.Blood Cancer J. 2021; 11: 1-4
- Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS).J Clin Oncol. 2020; 38: 8512
- Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).J Clin Oncol. 2021; 39: 8011
- Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.Lancet Oncol. 2021; 22: 1705-1720
- Sustained minimal residual disease negativity with daratumumab in newly diagnosed multiple myeloma: MAIA and ALCYONE.Blood. 2021; 139: 492-501
- Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR.J Clin Oncol. 2021; 39: 1139-1149
- Requirements for operational cure in multiple myeloma.Blood. 2021; 138: 1406-1411
- Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma.Blood Cancer J. 2020; 10: 1-7
- Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.Blood. 2011; 118: 529-534
- Curing myeloma at last: defining criteria and providing the evidence.Blood. 2014; 124: 3043-3051
- Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.Lancet Haematol. 2020; 7: e861-e873
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.Lancet Haematol. 2020; 7: e456-e468
- Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.N Engl J Med. 2017; 376: 1311-1320
- Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial.Blood. 2020; 136: 39
- Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.Lancet Haematol. 2021; 8: e422-e432
- Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.Blood Cancer J. 2021; 11: 1-9
- Measurable residual disease by next-generation flow cytometry in multiple myeloma.J Clin Oncol. 2019; 26https://doi.org/10.1200/JCO.19.01231
- Minimal residual disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM): results of the prognostic immunophenotyping for myeloma response (PRIMeR) study.Biol Blood Marrow Transplant. 2019; 25: S4-S6
- Sequential minimal residual disease (MRD) monitoring: Results from the UK Myeloma XI trial.Clin Lymphoma Myeloma Leuk. 2019; 19: e45-e46
- Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.Blood Adv. 2020; 4: 2163-2171
- Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis.J Clin Oncol. 2017; 35: 3279-3289
- Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.Ann Hematol. 2018; 97: 2425-2436
- CMS Enterprise Portal - Unauth Microstrategy Reports Link.(Available at:) (Accessed August 6, 2021)
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.J Clin Oncol. 2021; 13: 2101935https://doi.org/10.1200/JCO.21.01935
- Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.Blood Cancer J. 2018; 8: 26
- Competing risks and the clinical community: irrelevance or ignorance?.Stat Med. 2012; 31: 1089-1097
- The application of cure models in the presence of competing risks: a tool for improved risk communication in population-based cancer patient survival.Epidemiology. 2014; 25: 742-748
- Undetectable measurable residual disease (MRD) as endpoint of maintenance therapy: results from the TOURMALINE-MM3 Trial of Ixazomib vs placebo maintenance in newly diagnosed multiple myeloma (NDMM).(Available at:) (Accessed August 11, 2021)
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
